Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

ALRN Relative to the S&P 500

ALRN Relative to the Sector

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Aileron Therapeutics Inc. (NASD:ALRN) seasonal charts above shows that a Buy Date of December 29 and a Sell Date of April 15 has resulted in a geometric average return of 13.64% above the benchmark rate of the S&P 500 Total Return Index over the past 7 years. This seasonal timeframe has shown positive results compared to the benchmark in 5 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 7 years by an average of 67.43% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

A word of caution: Only 7 years of data is available for shares of ALRN, perhaps insufficient to create a seasonal profile that accurately gauges the seasonal tendencies influencing the investment. Ideally, while 20 years is preferred, at least 10 years of data is required to perform a seasonal analysis that is considered to be reliable for future seasonal periods.

Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company’s lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. The company currently has two product candidates in clinical development, LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications.

To download ALRN seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: ALRN